NCT06057051

Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma

A Prospective, Multicenter Study of the Glaukos® iStent Infinite Trabecular Micro-Bypass System Model iS3 in Subjects With Mild to Moderate Primary Open-angle Glaucoma

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 245 (estimated)
• Sponsor: Glaukos Corporation · Industry
• Sex: All
• Age: 35 Years
• Healthy volunteers: Not accepted

Summary

Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment

Conditions

• Glaucoma

Interventions

Type	Name	Description
DEVICE	iStent Infinite	iStent Infinite Trabecular Micro-Bypass System

Timeline

• Start date: 2023-09-01
• Primary completion: 2025-08-01
• Completion: 2027-08-01
• First posted: 2023-09-28
• Last updated: 2023-09-28

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study